All Posts
Review | Management of heart failure in patients with chronic kidney disease.
1 Aug, 2022 | 11:59h | UTCManagement of Heart Failure in Patients with Chronic Kidney Disease – European Cardiology Review
Cohort Study | Clinical outcomes and risk stratification of early-stage melanoma micrometastases.
1 Aug, 2022 | 12:04h | UTCClinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
‼️ Patients with low-risk (pT1b-pT2a) #melanoma may still develop high-risk sentinel node metastases ➡️ https://t.co/cBVdpR6xrG #JCO #melsm @marc_moncrieff pic.twitter.com/TW0WHp5brA
— Journal of Clinical Oncology (@JCO_ASCO) July 27, 2022
M-A | Prevalence of suicidal ideation and self-harm behaviors in children aged 12 years and younger.
1 Aug, 2022 | 12:01h | UTCPrevalence of suicidal ideation and self-harm behaviours in children aged 12 years and younger: a systematic review and meta-analysis – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
*New* systematic review & meta-analysis estimates a prevalence of 7·5% for suicidal ideation, 2·2% for suicide planning, 1·4% for self-harm, 1·3% for suicide attempts, & 21·9% for non-suicidal self-injury in children aged ≤12 years
In @TheLancetPsych #childhoodsuicide https://t.co/wFbv6eKpNs
— The Lancet Child & Adolescent Health (@LancetChildAdol) July 28, 2022
RCT | Efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder.
1 Aug, 2022 | 11:57h | UTC
Cohort Study | Association of assisted reproductive technology with offspring growth and adiposity from infancy to early adulthood.
1 Aug, 2022 | 11:54h | UTC
Commentary on Twitter
This cohort study found that differences in early growth and adiposity for people conceived via assisted reproductive technology (vs. naturally) were small and reduced with older age. @aelhak19 @DeborahLawlor2 https://t.co/hwdldN6yDf
— JAMA Network Open (@JAMANetworkOpen) July 26, 2022
M-A | Cardiovascular and venous thromboembolic risk with Janus Kinase inhibitors in immune-mediated inflammatory diseases.
1 Aug, 2022 | 11:52h | UTC
M-A | Endoscopic resection versus surgery in the treatment of early gastric cancer.
1 Aug, 2022 | 11:56h | UTC
Cohort Study | Rapid loss of smell predicts dementia and smaller brain areas linked to Alzheimer’s.
1 Aug, 2022 | 11:49h | UTCNews Release: Rapid loss of smell predicts dementia and smaller brain areas linked to Alzheimer’s – University of Chicago Medical Center
Original Study: Rapid olfactory decline during aging predicts dementia and GMV loss in AD brain regions – Alzheimer’s & Dementia
Single-arm phase 1b study | Venetoclax Plus Gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia.
1 Aug, 2022 | 11:46h | UTC
Commentary on Twitter
🙌 Venetoclax plus gilteritinib yields modified composite complete response of 75% in FLT3-mutated relapsed/refractory #AcuteMyeloidLeukemia
Read in #JCO ➡️ https://t.co/L7wxJ63qv9 #AML #leusm @Daver_Leukemia @jaltmanmd pic.twitter.com/ksXw1DNMsE
— Journal of Clinical Oncology (@JCO_ASCO) July 29, 2022
Single-arm phase 2 study | Lenvatinib plus Pembrolizumab for melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given as monotherapy or in combination.
1 Aug, 2022 | 11:48h | UTCPhase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression — More than a fifth of patients responded to lenvatinib-pembrolizumab combination – MedPage Today (free registration required)
Network M-A | Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease.
1 Aug, 2022 | 11:45h | UTCEfficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis – Gut (link to abstract – $ for full-text)
Systematic Review | Rapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection.
29 Jul, 2022 | 12:39h | UTCRapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection – Cochrane Library
Summary: How accurate are rapid antigen tests for diagnosing COVID-19? – Cochrane Library
M-A | Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes.
29 Jul, 2022 | 12:37h | UTCCommentaries:
No justification for bespoke antihypertensive intervention in type 2 diabetes – medwire News
Blood pressure control according to type 2 diabetes status – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Online—Blood pressure-lowering treatment for prevention of major #cardiovascular diseases in people with and without type 2 #diabetes: an individual participant-level data meta-analysis https://t.co/AmNxyW9Via #T2D #BloodPressure #hypertension #openaccess pic.twitter.com/NfdLktZXai
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 25, 2022
Position Paper | Red yeast rice for dyslipidemias and cardiovascular risk reduction.
29 Jul, 2022 | 12:35h | UTC
Systematic Review | Antiplatelet agents and anticoagulants for hypertension.
29 Jul, 2022 | 12:29h | UTCAntiplatelet agents and anticoagulants for hypertension – Cochrane Library
Summary: Antiplatelet agents and anticoagulants for high blood pressure – Cochrane Library
Commentary on Twitter
Do #antiplatelet agents & #anticoagulants improve outcomes in people with #hypertension?
Our newly updated @CochraneLibrary review looks at the evidence of 6 RCTs involving more than 61,000 participants: https://t.co/zaXP4YLg4n#CochraneEvidence #blogshot pic.twitter.com/X1DK2NTCtb
— Cochrane Hypertension (@CochraneHTN) July 28, 2022
ASTRO Guideline | Radiation therapy for IDH-mutant grade 2 and grade 3 diffuse glioma.
29 Jul, 2022 | 12:33h | UTC
M-A | Lung cancer occurrence after an episode of tuberculosis.
29 Jul, 2022 | 12:28h | UTC
Guideline | Pediatric differentiated thyroid carcinoma.
29 Jul, 2022 | 12:31h | UTC
A large observational study suggests long-acting injectable antipsychotics are associated with better outcomes than oral antipsychotics in people with schizophrenia.
29 Jul, 2022 | 12:25h | UTCInvited Commentary: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open
Related:
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link to abstract – $ for full-text)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)
Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Cohort Study | Impact of peridevice leak on 5-year outcomes after left atrial appendage closure.
29 Jul, 2022 | 12:26h | UTCImpact of Peridevice Leak on 5-Year Outcomes After Left Atrial Appendage Closure – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Commentary: Peridevice Leaks After LAA Occlusion Signal Poorer 5-Year Outcomes – TCTMD
Cohort Study | Assessment of second primary cancer risk among men receiving primary radiotherapy vs. surgery for the treatment of prostate cancer.
29 Jul, 2022 | 12:23h | UTC
Commentary on Twitter
In this cohort study of patients with localized prostate cancer, radiotherapy was associated with a small increase in the risk of developing a second primary cancer. https://t.co/YsrNo3FKwM
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
Cohort Study | Analysis of prescriptions for dual antiplatelet therapy after acute ischemic stroke.
29 Jul, 2022 | 12:20h | UTCRelated:
Commentary on Twitter
In this cohort study, dual antiplatelet of aspirin and clopidogrel was underused in patients with minor ischemic stroke and potentially overused in non-minor ischemic stroke, with substantial hospital variations. https://t.co/rZeGbMgF1E
— JAMA Network Open (@JAMANetworkOpen) July 28, 2022
M-A | Socioeconomic indicators of treatment prognosis for adults with depression.
29 Jul, 2022 | 12:17h | UTCNews Release: People without jobs or secure housing have worse outcomes when treated for depression – University College London
Commentary on Twitter
Socioeconomic disadvantage in employment and housing is associated with considerably worse outcomes in #depression, regardless of treatment type and after adjusting for clinical prognostic factors. https://t.co/bVTQv5zx8C
— JAMA Psychiatry (@JAMAPsych) May 6, 2022
RCT | Supplemental Vitamin D does not reduce incident fractures in midlife and older adults.
28 Jul, 2022 | 13:31h | UTCSupplemental Vitamin D and Incident Fractures in Midlife and Older Adults – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Daily Vitamin D supplements don’t lower risk of bone fractures, study finds – STAT
Related:
Commentary on Twitter
A study ancillary to a large trial showed that supplemental vitamin D3 did not lower the risk of fractures among generally healthy midlife and older adults not selected for vitamin D deficiency, low bone mass, or osteoporosis. https://t.co/vVTlizdffG pic.twitter.com/hQHJ7JizaV
— NEJM (@NEJM) July 27, 2022
Long-term results of a RCT | Active maintenance Olaparib vs. Placebo for germline BRCA-mutated metastatic pancreatic cancer.
29 Jul, 2022 | 12:18h | UTCOverall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
OS data from the POLO trial of maintenance olaparib vs placebo for pts with BRCA-mutant PDAC reveal no significant benefit (median 19.0 vs 19.2 months) although the curves separated at 24 months & 3-yr OS was 33.9% vs 17.8%; other outcomes favour olaparib: https://t.co/JZ28MsGV0B
— NatureRevClinOncol (@NatRevClinOncol) July 20, 2022